Pruritus - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 94 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Pruritus - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Pruritus - Pipeline Review, H2 2014', provides an overview of the Pruritus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pruritus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pruritus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pruritus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pruritus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pruritus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Pruritus Overview 9
Therapeutics Development 10
Pipeline Products for Pruritus - Overview 10
Pipeline Products for Pruritus - Comparative Analysis 11
Pruritus - Therapeutics under Development by Companies 12
Pruritus - Therapeutics under Investigation by Universities/Institutes 14
Pruritus - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Pruritus - Products under Development by Companies 18
Pruritus - Products under Investigation by Universities/Institutes 19
Pruritus - Companies Involved in Therapeutics Development 20
Johnson & Johnson 20
Shionogi & Co., Ltd. 21
GlaxoSmithKline plc 22
Merck & Co., Inc. 23
Santen Pharmaceutical Co., Ltd. 24
Amorepacific Corporation 25
LEO Pharma A/S 26
Nippon Shinyaku Co., Ltd. 27
RDD Pharma Ltd. 28
Toray Industries, Inc. 29
FAES Farma SA 30
Hydra Biosciences, Inc. 31
Cara Therapeutics, Inc. 32
ELORAC, Inc. 33
Vanda Pharmaceuticals Inc. 34
Creabilis SA 35
Trevi Therapeutics, Inc. 36
Conrig Pharma ApS 37
NeRRe Therapeutics Ltd 38
Pruritus - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
bilastine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
desloratadine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
naloxone hydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
nalbuphine hydrochloride ER - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
orvepitant maleate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CT-327 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
CR-845 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
nalfurafine hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NS-141 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
VLY-686 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PAC-14028 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecule for Pruritus - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
serlopitant - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
aprepitant - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
GSK-2330672 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules to Inhibit TRPV3 for Pain, Pruritus and Psoriasis - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
JNJ-7777120 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule to Agonize CB2 for Pruritus - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Drugs to Target Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SA-14867 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
CRG-010 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PP-120 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Pruritus - Recent Pipeline Updates 78
Pruritus - Dormant Projects 85
Pruritus - Discontinued Products 86
Pruritus - Product Development Milestones 87
Featured News & Press Releases 87
Mar 21, 2014: Creabilis to Present CT327 Phase 2b Data at American Academy of Dermatology Annual Meeting 87
Jan 23, 2014: Start of Phase II study of neurokinin-1 receptor antagonist orvepitant for intense pruritus induced by epidermal growth factor receptor inhibitors 88
Aug 19, 2013: Velocity Pharmaceutical Development and Tigercat Pharma Announce Submission of IND Application for VPD-737 89
Apr 12, 2013: Elorac's Naloxone Topical Lotion Receives FDA Fast Track Designation For Relief Of Pruritus In Patients With Cutaneous T-cell Lymphoma 89
Dec 22, 2011: Toray, Japan Tobacco And Torii Terminate Joint Development Of Nalfurafine Hydrochloride For Pruritus Associated With Liver Disease In Japan 90
Jul 21, 2011: Merz Aesthetics Announces FDA Approval Of XEOMIN For Temporary Improvement In Appearance Of Moderate To Severe Glabellar Lines In Adult Patients 90
Nov 30, 2010: Elorac Wins Orphan Drug Designation For Naloxone For Treatment Of Pruritus In Cutaneous T-Cell Lymphoma 90
Mar 23, 2009: Torii Pharma To Launch Remitch Capsules 2.5�g For Hemodialysis Patients 91
Jan 21, 2009: Toray Announces Manufacturing And Marketing Approval For Remitch Capsules 2.5�g In Japan 91
Apr 27, 2007: Schering-Plough declared EU Approval of Two New Formulations of AERIUS(Desloratadine). 91
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94

List of Tables
Number of Products under Development for Pruritus, H2 2014 10
Number of Products under Development for Pruritus - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Pruritus - Pipeline by Johnson & Johnson, H2 2014 20
Pruritus - Pipeline by Shionogi & Co., Ltd., H2 2014 21
Pruritus - Pipeline by GlaxoSmithKline plc, H2 2014 22
Pruritus - Pipeline by Merck & Co., Inc., H2 2014 23
Pruritus - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 24
Pruritus - Pipeline by Amorepacific Corporation, H2 2014 25
Pruritus - Pipeline by LEO Pharma A/S, H2 2014 26
Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 27
Pruritus - Pipeline by RDD Pharma Ltd., H2 2014 28
Pruritus - Pipeline by Toray Industries, Inc., H2 2014 29
Pruritus - Pipeline by FAES Farma SA, H2 2014 30
Pruritus - Pipeline by Hydra Biosciences, Inc., H2 2014 31
Pruritus - Pipeline by Cara Therapeutics, Inc., H2 2014 32
Pruritus - Pipeline by ELORAC, Inc., H2 2014 33
Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H2 2014 34
Pruritus - Pipeline by Creabilis SA, H2 2014 35
Pruritus - Pipeline by Trevi Therapeutics, Inc., H2 2014 36
Pruritus - Pipeline by Conrig Pharma ApS, H2 2014 37
Pruritus - Pipeline by NeRRe Therapeutics Ltd, H2 2014 38
Assessment by Monotherapy Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 42
Number of Products by Stage and Mechanism of Action, H2 2014 45
Number of Products by Stage and Route of Administration, H2 2014 47
Number of Products by Stage and Molecule Type, H2 2014 49
Pruritus Therapeutics - Recent Pipeline Updates, H2 2014 78
Pruritus - Dormant Projects, H2 2014 85
Pruritus - Discontinued Products, H2 2014 86